Tumor-imaging compounds show promise, Molecular Insight says

12/30/2008 | Mass High Tech (Boston)

Molecular Insight Pharmaceuticals said preliminary trial results showed that its molecular-imaging compounds, MIP-1072 and MIP-1095, exhibited high affinity to a protein expressed by prostate tumors. The company said it intends to finish early-stage trials of the compounds by the first half of next year.

View Full Article in:

Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC